Navient (NASDAQ:NAVI) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.79 by 16.46 percent. This is a 6.12 percent decrease over earnings of $0.98 per share from the same period last year.
Datopotamab Deruxtecan Showed Encouraging, Durable Efficacy In Patients With Heavily Pretreated HR Positive, HER2 Low Or Negative Metastatic Breast Cancer
First results for Daiichi Sankyo and AstraZeneca's TROP2 directed ADC in this setting reported from TROPION-PanTumor01 phase 1 trial
Pivotal TROPION-Breast01 phase 3 trial is ongoing, evaluating datopotamab